Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial

This randomized, double-blind, crossover study examined the efficacy and safety of gefapixant versus placebo for the treatment of chronic cough in 51 patients with IPF. The primary endpoint was change from baseline in awake objective cough frequency (coughs/hour) from the placebo and gefapixant treatment periods combined. Secondary endpoints included: change in awake objective cough frequency from each treatment period, change in 24-hour objective cough frequency from both treatment periods combined and from each treatment period separately; change in sleep cough frequency from both treatment periods combined; and cough frequency responder endpoints. In each treatment period, objective 24-hour cough monitoring was undertaken at baseline and 7 and 14 days after administration of study treatment using the Vitalograph VitaloJAK device.